Tag Archive for: biopharmaceutical

vasopharm GmbH Announces Brain Glutamate Microdialysate Data from Post Hoc Analyses of Clinical Trials in Traumatic Brain Injury

Ronopterin significantly reduces glutamate levels measured in brain microdialysate from TBI patients, an important and long sought indicator of biochemical neuroprotection Combined inhibition of nitric oxide synthesis and glutamate increase expands our understanding of Ronopterin’s mode of action and its association with improved outcome in TBI Decreasing glutamate adds to the previously reported reduction in […]

Verona Pharma Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

Phase 3 ENHANCE program on track to report top-line COPD data in 2022 Conference call today at 9:00 a.m. EST / 2:00 p.m. GMT LONDON and RALEIGH, N.C., March 03, 2022 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces its financial […]

vasopharm GmbH Announces Post Hoc Analyses of Clinical Trials in Traumatic Brain Injury

Improved neurologic outcome in young adults (18-39 years) with Ronopterin infused early Significantly less aggressive critical care with maintained renal function in young adults New patent filed for efficacious treatment window Discussions with US and EU regulators to support market authorization initiated vasopharm GmbH, a privately-held biopharmaceutical company focusing on novel therapeutics to treat cerebrovascular […]